Radiprodil
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infantile Spasms (IS)
Conditions
Infantile Spasms (IS)
Trial Timeline
Dec 4, 2017 → Oct 2, 2018
NCT ID
NCT02829827About Radiprodil
Radiprodil is a phase 2 stage product being developed by UCB for Infantile Spasms (IS). The current trial status is terminated. This product is registered under clinical trial identifier NCT02829827. Target conditions include Infantile Spasms (IS).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02829827 | Phase 2 | Terminated |
Competing Products
16 competing products in Infantile Spasms (IS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 36 |
| MAS825 + Placebo | Novartis | Phase 2 | 52 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 84 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 20 |
| Sabril® | Lundbeck | Pre-clinical | 20 |
| Vigabatrin | Lundbeck | Approved | 82 |
| Nusinersen | Biogen | Pre-clinical | 20 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| Cerliponase Alfa | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Cholic Acids | Mirum Pharmaceuticals | Phase 3 | 74 |
| Cipaglucosidase alfa + Miglustat | Amicus Therapeutics | Phase 3 | 74 |
| ATB200 + AT2221 | Amicus Therapeutics | Pre-clinical | 20 |
| RP-L401 | Rocket Pharmaceuticals | Phase 1 | 25 |